Our Take
A supply-chain consolidation play masquerading as expansion: Boston Scientific is co-locating distribution with manufacturing to cut handling, transit time, and overhead, not to enter new markets.
Why it matters
Medtech companies operate on tight margins and regulatory timelines. Proximity between manufacturing and distribution directly reduces inventory holding costs and accelerates time-to-patient for hospitals and clinics that depend on just-in-time device restocking.
Do this week
Supply chain leads at medtech vendors: audit your current distance between manufacturing and distribution; if you're shipping finished devices more than 500 miles to your primary fulfillment hub, model the capex and cash-flow impact of co-location before next fiscal planning cycle.
Boston Scientific site location and facility scope
Boston Scientific announced plans to build a distribution center in Indiana positioned adjacent to an existing principal manufacturing facility. The facility will handle global distribution of the company's medical devices portfolio, consolidating logistics operations that presumably operate separately today or from distant hubs.
No timeline, capital expenditure, or job-creation numbers were disclosed in the announcement (per MedTech Dive). The company has not specified which device categories will flow through the center or which current distribution locations it may replace or supplement.
Supply-chain efficiency in medtech manufacturing
Medtech companies face a unique logistics constraint: devices must move quickly from manufacturing to end-user without long dwell times in storage, because hospitals and surgery centers operate on just-in-time inventory models to minimize capital tied up in stock. Distance between manufacturing and distribution directly affects fulfillment cycle time and holding costs.
Co-locating distribution with manufacturing eliminates intermediate transport legs, reduces inventory in transit, and shortens the span between production quality checks and customer receipt. For a company like Boston Scientific, which manufactures across multiple platforms (cardiac, endoscopy, urology, oncology), a centralized hub near manufacturing also simplifies secondary sorting and kitting operations for regional orders.
The Indiana location choice suggests the company is anchoring logistics to a region where it already maintains substantial manufacturing footprint, not expanding into new geography. This is an efficiency play, not a market expansion.
What operations teams should evaluate
If you manage supply-chain operations at a medtech manufacturer, this move is a signal to pressure-test your own distribution strategy. Calculate the total cost of ownership for your current network: production-to-warehouse transport, storage, labor, handling damage, and order-fulfillment cycle time from each hub. Compare it against the capex required to co-locate distribution at your largest manufacturing site.
Most medtech companies inherit distribution footprints designed for a different product mix or customer base than they serve today. A formal network optimization study every 3-5 years, benchmarked against peers, typically uncovers 10-15% logistics savings without harming service levels. If Boston Scientific is making this move, it is because the math works at scale.